Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference

Mizuho identified Snowflake as its top pick in the software largecap sector, citing 37% year-over-year revenue growth and strong AI product demand. The company raised its fiscal year 2027 product revenue growth outlook to 36% and received multiple price target increases from other firms. Mizuho maintains an Outperform rating and raised its price target to $425.

Tesla began offering paid rides in its Cybercab, a fully autonomous vehicle without a steering wheel, designed for passenger transport. The Cybercab, produced in Austin, Texas, is not yet available to the general public. Tesla's stock, valued at $1.5 trillion, relies on its dominance in autonomous vehicle technology. Analysts note that a broader rollout could impact Tesla's stock performance. The company faces competition from Waymo and regulatory challenges.

Moderna's stock (MRNA) has pulled back from recent highs despite a 404% year-to-date gain. The company reported positive phase 3 trial results for its cancer vaccine, intismeran autogene, in collaboration with Merck. Analysts estimate potential peak revenue of $5.6 billion for the vaccine, shared equally with Merck. Moderna also gained FDA approval for its flu vaccine, mFLUSIVA. Despite a high valuation, the company's pipeline and clinical progress make it an attractive long-term investment, acc

Apple's foldable iPhone production is limited to a few hundred units per day due to quality checks, according to Nikkei Asia sources. The slow ramp-up may result in limited supply at launch, potentially falling short of the 8-10 million unit target. Apple is focusing on screen flatness and hinge performance, with stricter testing than competitors.

AMD launched the Ryzen AI Max PRO 400 series, featuring 192GB unified memory for local AI model inference. The chips, available in three SKUs, support up to 300B-parameter models at 4-bit quantization. Commercial systems from HP and Lenovo are expected by Q3 2026. AMD claims the architecture eliminates PCIe bottlenecks, offering 273 GB/s memory bandwidth. The lineup includes the 495, 490, and 485 models, with varying core counts and performance. AMD's offering competes with NVIDIA's DGX and RTX

Xenon Pharmaceuticals (XENE) will present data on azetukalner, a potential epilepsy treatment, at the European Epilepsy Congress. The company reported a net loss of $110.7M in Q2 2026, up from $84.7M a year earlier, due to increased R&D and administrative costs. Xenon expects to file for FDA approval of azetukalner in Q3 2026 and is also testing the drug for depression and pain.